Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 2 1

Status

Completed 13Recruiting 12Active not recruiting 6Unknown 5Not yet recruiting 4Terminated 3Enrolling by invitation 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Neoplasms 6Hematologic Neoplasms 5Breast Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Glioma 3Colorectal Neoplasms 3Prostatic Neoplasms 2Neoplasms by Site 2Motor Activity 2Head and Neck Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Anxiety Disorders 2Anatomic Stage I Breast Cancer AJCC v8 2Uveal Melanoma 1Uterine Neoplasms 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Stomatitis 1Stomach Neoplasms 1Smoking Cessation 1Small Cell Lung Carcinoma 1

Interventions

Irinotecan 58Bevacizumab 56Oxaliplatin 49Leucovorin 49Fluorouracil 49Capecitabine 45Cetuximab 44pembrolizumab 23IFL protocol 15Nivolumab 11regorafenib 10Panitumumab 10Celecoxib 8Radiotherapy 7Cyclophosphamide 7atezolizumab 6Surgical Procedures, Operative 6Gemcitabine 6Folfox protocol 6Colonoscopy 6trifluridine tipiracil drug combination 5Neoadjuvant Therapy 5Metformin 5Immunohistochemistry 5Biopsy 5tislelizumab 4spartalizumab 4durvalumab 4Trastuzumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Colorectal Neoplasms × Standard of Care × Clear all
NCT01468623 2023-07-19

PROFUSE

Myriad Genetic Laboratories, Inc.

Phase 4 Terminated
51 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02597075 2022-11-07

Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy

Swiss Cancer Institute

Phase NA Terminated
100 enrolled
Gastrointestinal

Motor Activity, Colorectal Neoplasms

NCT02448810 2021-05-25

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Takeda

Phase 2 Terminated
115 enrolled 22 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡